4-(3-Nitrophenyl)oxazole | 521983-15-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-Nitrophenyl)oxazole
• 英文别名: 4-(3-nitrophenyl)-1,3-oxazole
• CAS: 521983-15-3
• 化学式: C9H6N2O3
• 分子量: 190.16
• InChiKey: XZAOBFPZZWWNMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON
  申请人：Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma"

  公开号：EP2743266A2

  公开（公告）日：2014-06-18

  The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

  本发明涉及借助新系列化合物治疗肿瘤、慢性炎症和类似疾病，这些化合物在抑制 Abl 激酶及其突变形式以及其他具有治疗意义的激酶方面具有更高的效率。它描述了通式（I）化合物和通式（II）化合物或其同分异构体、单个异构体、异构体混合物、药学上可接受的盐、溶液或水合物形式的蛋白激酶抑制剂。
• FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
  申请人：Metacrine, Inc.

  公开号：EP3852736A1

  公开（公告）日：2021-07-28
• [EN] OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS<br/>[FR] COMPOSES D'OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE, ET METHODES DE TRAITEMENT DE TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER AG

  公开号：WO2003040141A1

  公开（公告）日：2003-05-15

  Disclosed are oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and derivatives thereof having the formula (I) or (II): wherein A is oxazolyl which is optionally substituted by halogen, linear or branched C1-C5 alkyl and R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as described in the specification. Also disclosed are methods of making the oxazolyl-phenyl-2,4-diamino-pyrimidine compounds. The compounds are S-phase elevated kinase (SPEK) inhibitors and are useful in the treatment of hyperproliferative diseases.
• [EN] FARNESOID X RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR FARNÉSOÏDE X ET LEURS UTILISATIONS
  申请人：METACRINE INC

  公开号：WO2020061117A1

  公开（公告）日：2020-03-26

  Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.